Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690521 | PMC |
| http://dx.doi.org/10.1155/2009/635194 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series.
Biomedicines
December 2024
Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
: The current possible treatments of advanced medullary carcinoma (MTC) include different drugs belonging to the class of tyrosine kinase inhibitors (TKIs): vandetanib, cabozantinb, and selpercatinib. Although the effects of these TKIs have been well described in clinical trials, the real-practice evidence of the effectiveness and safety of these treatment is scant. This real-world case series aims to describe a niche of patients with advanced MTC treated with more than one TKI by focusing on treatment responses and any reported adverse events (AEs) and to provide additional insight on the individualized approach to the management of metastatic MTC.
View Article and Find Full Text PDFIdentification of Factors Determining Patterns of Serum C-Reactive Protein Level Reduction in Response to Treatment Initiation in Patients with Drug-Susceptible Pulmonary Tuberculosis.
Antibiotics (Basel)
December 2024
Pharmacogenetic and Precision Medicine Laboratory, Pharmaceutical Education and Research Centre, Riga Stradins University, Konsula Street 21, LV1007 Riga, Latvia.
Serum C-reactive protein (CRP) levels vary depending on radiological and bacteriological findings at the time of tuberculosis (TB) diagnosis. However, the utility of this biomarker in monitoring response to anti-TB treatment and identifying patients at risk of treatment failure is not well established. This study evaluated the impact of patients' baseline characteristics and anti-TB drug plasma exposure on the early reduction in serum CRP levels and its relationship with treatment response.
View Article and Find Full Text PDFThe impact of SMARCA4 loss in non-small cell lung cancer therapy.
Heliyon
January 2025
Department of Thoracic Surgery, IEO, European Institute of Oncology, IRCCS, Milan, Italy.
This case report explores the therapeutic impact of SMARCA4 loss in a 63-year-old female patient with a history of smoking, hypertension, hypercholesterolemia, and prior surgeries for breast and pancreatic carcinomas, who presented with a new pulmonary nodule. On February 23, 2024, a CT scan identified a solid pulmonary nodule in the right lower lobe. A PET scan confirmed the nodule's metabolic activity.
View Article and Find Full Text PDFChlamydia psittaci pneumonia - evolutionary aspects on chest CT.
BMC Infect Dis
January 2025
Department of Radiology, The Affiliated Brain Hospital of Nanjing Medical University, No.264, Guangzhou Road, Gulou District, Nanjing, 210029, Jiangsu, China.
Purpose: To present the different findings of Chlamydia psittaci (C. psittaci) pneumonia on computed tomography (CT) according to the progression of the disease, to improve diagnostic accuracy, guide early clinical diagnosis, evaluate treatment efficacy, and reduce the mortality associated with the disease.
Methods: In total, 80 cases of C.
Comparison of CT findings between basaloid squamous cell carcinoma and non-basaloid squamous cell carcinoma of the lung.
Sci Rep
December 2024
Department of Radiology, Veterans Health Service Medical Center, Seoul, Republic of Korea.
This study aimed to compare computed tomography (CT) findings between basaloid lung squamous cell carcinoma (SCC) and non-basaloid SCC. From July 2003 to April 2021, 39 patients with surgically proven basaloid SCC were identified. For comparison, 161 patients with surgically proven non-basaloid SCC from June 2018 to January 2019 were selected consecutively.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!